AIM: To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's disease patients after adalimumab failure. METHODS: A historical cohort study in a community-based gastroenterology practice evaluated Crohn's disease patients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA). RESULTS: We included 15 Crohn's disease patients who received infliximab after adalimumab failure. Five patients discontinued adalimumab due to loss of response, 3 due to adverse events and 7 due to partial response. After infliximab therapy was started, all patients who had interrupted adalimumab due to loss of efficacy regained response. All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab, but 2 developed adverse events. None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab. CONCLUSION: Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response, however, the benefit of infliximab in primary nonresponders was not established.
AIM: To evaluate the effectiveness of infliximab as a second-line therapy in Crohn's diseasepatients after adalimumab failure. METHODS: A historical cohort study in a community-based gastroenterology practice evaluated Crohn's diseasepatients treated with infliximab (induction plus maintenance) after adalimumab failure. Patients were identified using a large Spanish database (ENEIDA). RESULTS: We included 15 Crohn's diseasepatients who received infliximab after adalimumab failure. Five patients discontinued adalimumab due to loss of response, 3 due to adverse events and 7 due to partial response. After infliximab therapy was started, all patients who had interrupted adalimumab due to loss of efficacy regained response. All patients who discontinued adalimumab due to adverse events responded to infliximab and maintained this response; one of these patients had an uneventful course on infliximab, but 2 developed adverse events. None of the 7 patients who interrupted adalimumab due to partial response reached remission with infliximab. CONCLUSION: Switching from adalimumab to infliximab may be useful in patients who develop adverse effects or loss of response, however, the benefit of infliximab in primary nonresponders was not established.
Authors: Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382
Authors: Konstantinos Karmiris; Gilles Paintaud; Maja Noman; Charlotte Magdelaine-Beuzelin; Marc Ferrante; Danielle Degenne; Karolien Claes; Tamara Coopman; Nele Van Schuerbeek; Gert Van Assche; Severine Vermeire; Paul Rutgeerts Journal: Gastroenterology Date: 2009-08-05 Impact factor: 22.682
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: William J Sandborn; Stephen Hanauer; Edward V Loftus; William J Tremaine; Sunanda Kane; Russell Cohen; Karen Hanson; Therese Johnson; Debra Schmitt; Resa Jeche Journal: Am J Gastroenterol Date: 2004-10 Impact factor: 10.864
Authors: Adrienne Youdim; Eric A Vasiliauskas; Stephan R Targan; Konstantinos A Papadakis; Andrew Ippoliti; Marla C Dubinsky; Juan Lechago; Jane Paavola; Jaime Loane; Susie K Lee; Joanne Gaiennie; Katie Smith; Jason Do; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2004-07 Impact factor: 5.325
Authors: E William St Clair; Carrie L Wagner; Adedigbo A Fasanmade; Benjamin Wang; Thomas Schaible; Arthur Kavanaugh; Edward C Keystone Journal: Arthritis Rheum Date: 2002-06
Authors: Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245